palazestrant
palazestrant: sourced relationships with 1 company · 6 clinical trials tracked.
palazestrant evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could palazestrant → OLMA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) Breast Cancer; Advanced or Metastatic ER+ HER2- Breast Cance… | Phase 3 |
| Olema Pharmaceuticals, Inc. (OLMA) Breast Cancer; Advanced or Metastatic ER+ HER2- Breast Cance… | Phase 3 |
Clinical Trial Registry Records (6)
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
Primary endpoint: Progression-Free Survival (PFS)
A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors
Primary endpoint: Number of participants with dose-limiting toxicities in the Dose Escalation Arms
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Primary endpoint: Dose-Selection Part: Incidence of adverse events
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer
Primary endpoint: Dose Limiting Toxicities (DLTs)
A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer
Primary endpoint: Incidence of Dose Limiting Toxicities
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer
Primary endpoint: Dose Limiting Toxicities (DLT)
Frequently asked questions
Which companies have sourced relationships with palazestrant?
palazestrant has dated SEC/FDA relationship records for Olema Pharmaceuticals, Inc..
How many clinical trials involve palazestrant?
BioSniper tracks 6 clinical trials involving palazestrant.